Figure 1.

Effects of EFdA and other RTIs on 24 chimeric viruses representing HIV-1B (n = 5), HIV-1C (n = 15), HIV-1A1 (n = 1), HIV-1-01_AE (n = 1), HIV-1-02_AG (n = 2) and WT reference pNL4-3. (a) Intra-drug comparative analysis of the log₂ EC₅₀. Each virus is represented by a single circle on the graph. The log₂ median EC₅₀ value and IQR are indicated. Significant differences are shown as P values obtained from performing the Mann–Whitney test for each of two drugs. The actual EC₅₀ values are presented as median (IQR) below each drug abbreviation. The G190A contacting viruses were excluded from the median EC₅₀ analysis of nevirapine. Subtype-specific comparisons for (b) etravirine and (c) rilpivirine on HIV-1B, HIV-1C and HIV-1A-like viruses. The median EC₅₀ value and IQR are indicated. Significant differences were found for etravirine (P = 0.004) and rilpivirine (P = 0.017). Statistical analyses were performed using the Kruskal–Wallis test. TAF, tenofovir alafenamide; RPV, rilpivirine; ETR, etravirine; EFV, efavirenz; NVP, nevirapine.